Abstracts tagged "Behcet’s syndrome and outcome measures"

Abstract Number: 1793 • 2018 ACR/ARHP Annual Meeting
The Omeract Core Domain Set for Clinical Trials in Behçet’s Syndrome
Gulen Hatemi¹, Alexa Meara², Yesim Ozguler³, Haner Direskeneli⁴, Alfred Mahr⁵, Beverly Shea⁶, Esen Cam⁷, Ahmet Gül⁸, Yusuf Yazici⁹, Peter Tugwell¹⁰, Hasan Yazici¹¹ and Peter A. Merkel¹², ¹Istanbul University Cerrahpasa Medical School, Istanbul, Turkey, ²Internal Medicine/Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ³Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ⁴Rheumatology, Marmara University, School of Medicine Hospital, Istabul, Turkey, ⁵Hôpital Saint-Louis (Hôpitaux Universitaires Saint-Louis), Paris, France, ⁶Bruyere Research Institute, Ottawa, ON, Canada, ⁷The Univeristy of Istanbul, Istanbul, Turkey, ⁸Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ⁹New York University School of Medicine, New York, NY, ¹⁰Center For Global Health, Institute of Population Hlth, Ottawa, ON, Canada, ¹¹Division of Rheumatology,, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ¹²Division of Rheumatology and the Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA
Background/Purpose: There is an unmet need for reliable, validated, and widely-accepted outcome measures for clinical trials in Behçet’s syndrome (BS). The Outcome Measures in Rheumatology…
Abstract Number: 2755 • 2014 ACR/ARHP Annual Meeting
Disease Activity and Quality of Life in BEHÇET’S Disease: The Role of Patients Reportedoutcomes
Elena Elefante¹, Rosaria Talarico², Chiara Stagnaro³, Anna d'Ascanio⁴, Antonio Tavoni⁵, Chiari Tani¹, Chiara Baldini¹, Marta Mosca⁶ and Stefano Bombardieri², ¹University of Pisa, Rheumatology Unit, Pisa, Italy, ²Rheumatology Unit, Pisa, Italy, ³Rheumatology Unit, University of Pisa, Pisa, Italy, ⁴Internal Medicine, University of Pisa, Pisa, Italy, ⁵University of Pisa, Immunoallergology Unit, Pisa, Italy, ⁶V. Roma 67, 56126 Pisa, S. Chiara, Pisa, Italy
Background/Purpose Behçet’s disease (BD) is a systemic vasculitis, typically characterised by recurrent oro-genital ulcers, ocular inflammation and skin manifestations; articular, vascular, gastro-enteric and neurological involvement…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].